Successful immune tolerance induction consisting of high-dose factor VIII rich in von Willebrand factor and pulsed intravenous immunoglobulin: a case report
© Kubisz et al.; licensee BioMed Central Ltd. 2012
Received: 18 April 2012
Accepted: 10 September 2012
Published: 11 October 2012
The development of factor VIII inhibitors is a serious complication of replacement therapy in patients with congenital hemophilia A. Immune tolerance induction has been accepted as the only clinically proven treatment allowing antigen-specific tolerance to factor VIII. However, some of its issues, such as patient selection, timing, factor VIII dosing, use of immunosuppressive or immunomodulatory procedures, still remain the subject of debate.
A case of a 3-year-old Caucasian boy with severe congenital hemophilia A, intron 22 inversion of the F8 gene and high-titer inhibitor, who underwent an immune tolerance induction according to the modified Bonn regimen (high doses of plasma-derived factor VIII rich in von Willebrand factor and pulsed intravenous immunoglobulin) is presented. The treatment lasted for 13 months and led to the eradication of inhibitor.
Addition of intravenous immunoglobulin did not negatively affect the course of immune tolerance induction and led to the rapid eradication of factor VIII inhibitor.
KeywordsCoagulation factor VIII inhibitor Hemophilia A Immune tolerance induction Intravenous immunoglobulin Recombinant activated factor VII
The development of factor VIII (FVIII) inhibitors is a serious complication of replacement therapy in patients with congenital hemophilia A, affecting up to 35%, predominantly those with severe disease. It leads to the failure of previously efficient replacement therapy or prophylaxis with FVIII and thus to an increased risk of bleeding, joint impairment and reduced quality of life. Immune tolerance induction (ITI) has been accepted as the only clinically proven treatment allowing antigen-specific tolerance to FVIII[2, 3]. However, some of its issues, such as patient selection, timing, FVIII dosing, use of immunosuppressive or immunomodulatory procedures, still remain unclear. Several modifications of the first ITI treatment proposed in Bonn (Bonn regimen) have been described, but none have been proved to be superior[3–7].
We present a successful use of the high-dose FVIII regimen for ITI: plasma-derived FVIII rich in von Willebrand factor (vWF) and pulsed intravenous immunoglobulin (IVIG). The high-dose FVIII regimen was used in a 3-year-old Caucasian boy with severe congenital hemophilia A (endogenous FVIII level below 0.01IU/mL), the intron 22 inversion of the F8 gene and high-titer FVIII inhibitor. The patient was treated with on-demand replacement therapy with a single human plasma-derived FVIII concentrate rich in vWF (Fanhdi®, Grifols, Barcelona, Spain) from the age of 2 months. The initial choice of FVIII concentrate was made according to the availability of FVIII products at the start of the treatment. The FVIII inhibitor in a high titer occurred after 2 years of treatment and 20 exposure days (initial inhibitor titer (IT): 5.4BU/mL; Day −453, 453 days before the start of ITI). In order to prevent further immunization, FVIII was omitted from the treatment and on-demand recombinant activated factor VII (rFVIIa; NovoSeven®, NovoNordisk®, Bagsværd, Denmark) was used instead for maintaining hemostasis. The activated prothrombin complex concentrate factor VIII inhibitor bypass activity (FEIBA [factor eight inhibitor bypass activity]; Baxter International Inc., Deerfield, IL, USA) was not preferred due to the known risk of anamnestic response and prolongation of time period necessary for IT decrease. Within 14 months IT spontaneously decreased to 0.8BU/mL and thus, at the age of 3 years and 20 days, the first ITI could be started. The previously described ITI regimen – a combination of high doses of FVIII as in the original Bonn protocol (100IU/kg intravenous (IV) twice a day; the same FVIII concentrate as in the previous treatment) and pulsed IVIG (1g/kg IV on Days 0, 1, 7, 15 and 21; Kiovig, Baxter AG, Wien, Austria) – was used.
Only one serious hemorrhage (intramuscular in the left thigh; Day 21 of ITI) occurred; its cessation was achieved solely with bypass therapy. However, ITI was complicated with severe bacterial infections associated with CVAD (three episodes of catheter-related sepsis; Days 25, 188, and 216 of ITI).
The prophylactic re-treatment with the same plasma-derived FVIII (Fanhdi®1000IU IV thrice a week without gradual tapering) was initiated after ITI termination. During a 10-month follow-up, no clinical or laboratory signs of FVIII inhibitor and no severe bleeding appeared.
Although current knowledge of ITI is based predominantly on results of uncontrolled retrospective studies, case reports and patient registries (International Immune Tolerance Registry, German Registry, North American Immune Tolerance Registry) with limited directed comparison of different regimens, it is commonly accepted that the outcome of ITI is worse in patients with IT more than 10BU/mL at ITI initiation, historical IT more than 200BU/mL and peak IT on ITI more than 250BU/mL[3, 7]. Other negative factors – age over 20 years at beginning of ITI, persistence of inhibitor for more than 5 years, use of FVIII concentrates without vWF, presence of null mutations within F8 gene, African origin, and inflammatory challenges during ITI – were suggested by particular analyses[7–13]. However, the available clinical data on those parameters are not consistent and sufficient for their general acceptance. The recently finished International Immune Tolerance Study, involving 115 good-risk patients with severe congenital hemophilia A and high-titer inhibitor on ITI, verified the inverse correlation of historical IT and peak IT on ITI with the treatment success, but failed to show a significant effect of infections on its outcome.
The positive effect of IVIG addition to ITI has been reported since the introduction of the Malmö protocol[3, 15]. The rapid, although time-limited, improvement in FVIII pharmacokinetics and decrease in IT, accompanied by lower bleeding tendency, was attributed to IVIG. However, these reports are anecdotal and limited almost exclusively to case reports. Therefore, a recent international consensus recommendation does not approve the standard use of IVIG or other immunomodulating agents in first-line ITI.
In the presented case, the patient had a good prognostic profile, with the low initial, historical, and anamnestic IT and with only one known negative factor (intron 22 inversion). The treatment was well tolerated with relatively rare bleedings. CVAD-related sepsis was regarded as the most serious complication. The infections, although recurrent and associated with the transient elevation of IT, did not result in a marked prolongation of ITI. The normalization of FVIII pharmacokinetics was seen after 13 months, so the ITI duration was comparable with the mean durations reported in the analyses of patient registries[3, 7]. The use of IVIG could, similarly to the observations of other authors, contribute to the relatively low frequency of severe hemorrhages and the normal ITI duration despite repeated inflammatory challenges[4, 12].
The bleeding episodes in hemophilia patients with high-titer inhibitor, both prior to and during ITI, are managed with bypass agents: rFVIIa and activated prothrombin complex concentrate FEIBA. Both agents are comparable in terms of efficacy and safety. However, the ability of FEIBA to induce anamnestic response, and thus prolong the persistence of inhibitor, is a possible drawback for its use in ITI. Although the negative effect of this phenomenon on ITI outcome is not clear, FEIBA is nowadays not recommended for the first-line treatment in patients planned for ITI. In concordance with the standard practice, rFVIIa was preferred in the presented case.
We report a successful use of ITI consisting of high-dose plasma-derived FVIII rich in vWF and IVIG in a hemophilia patient with high-titer FVIII inhibitor and intron 22 inversion. The addition of IVIG did not alter the course of ITI or the patient’s condition.
Written informed consent was obtained from the patient’s legal guardian (mother) for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Central venous access device
Factor VIII inhibitor bypass activity
Immune tolerance induction
Recombinant activated factor VII
von Willebrand factor.
- Green D: Factor VIII inhibitors: a 50-year perspective. Haemophilia. 2011, 17: 831-838. 10.1111/j.1365-2516.2011.02568.x.View ArticlePubMedGoogle Scholar
- Franchini M, Lippi G: Immune tolerance induction for patients with severe hemophilia A: a critical literature review. J Thromb Thrombolys. 2011, 32: 439-447. 10.1007/s11239-011-0624-3.View ArticleGoogle Scholar
- DI Michele DM: Immune tolerance induction in haemophilia: evidence and the way forward. J Thromb Haemost. 2011, 9 (Suppl. 1): 216-225.View ArticlePubMedGoogle Scholar
- Mauz-Korholz C, Korholz D, Gobel U: Rapid elimination of a high-titered F VIII inhibitor by high dose recombinant F VIII combined with high dose immunoglobulin infusion. Thromb Haemost. 1997, 78: 959-PubMedGoogle Scholar
- Brackmann HH, Oldenburg J, Schwaab R: Immune tolerance for the treatment of factor VIII inhibitors - twenty years of the Bonn Protocol. Vox Sang. 1996, 70: 30-35.View ArticlePubMedGoogle Scholar
- Coppola A, Di Minno MN, Santagostino E: Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol. 2010, 150: 515-528. 10.1111/j.1365-2141.2010.08263.x.View ArticlePubMedGoogle Scholar
- DiMichele D: The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia. 2009, 15: 320-328. 10.1111/j.1365-2516.2008.01880.x.View ArticlePubMedGoogle Scholar
- Kreuz W, Escuriola-Ettingshausen C, Auerswald G, Heidemann P, Kemkes-Matthes B, Schneppenheim R: Immune tolerance induction (ITI) in haemophilia A with inhibitors: the choice of concentrate affecting success. Haematologica. 2001, 86 (Suppl. 4): 16-20.Google Scholar
- Coppola A, Margaglione M, Santagostino E, Rocino A, Grandone E, Mannucci PM, Di Minno G, for the AICE PROFIT Study Group: Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of patients with severe hemophilia A and high-responding inhibitors. J Thromb Haemost. 2009, 7: 1809-1815. 10.1111/j.1538-7836.2009.03615.x.View ArticlePubMedGoogle Scholar
- Callaghan MU, Rajpurkar M, Chitlur M, Warrier I, Lusher J: Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans?. Haemophilia. 2011, 17: 483-489. 10.1111/j.1365-2516.2010.02429.x.View ArticlePubMedGoogle Scholar
- Di Minno G, Coppola A: A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors?. Blood Transfus. 2011, 9 (Suppl. 2): s14-s20.PubMedPubMed CentralGoogle Scholar
- Santagostino E, Mancuso ME: Venous access in haemophiliac children: choice and management. Haemophilia. 2010, 16 (Suppl. 1): 20-24.View ArticlePubMedGoogle Scholar
- Benson G, Auerswald G, Elezović I, Lambert T, Ljung R, Morfini M, Remor E, Salek SZ: Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice. Eur J Haematol. 2012, 88: 371-379. 10.1111/j.1600-0609.2012.01754.x.View ArticlePubMedGoogle Scholar
- Hay CR, DiMichele DM: The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012, 119: 1335-1344. 10.1182/blood-2011-08-369132.View ArticlePubMedGoogle Scholar
- Stiefel M, Pinkwart C, Haase R, Merkel N, Forsberg D, Mauz-Körholz C: Immune tolerance induction with high-dose FVIII and pulsed intravenous immunoglobulin. Hämostaseologie. 2010, 30 (Suppl. 1): S119-S121.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.